A practical reference on MC4R: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2025-12-03 and is reviewed periodically as new material appears.
Approved use is narrow and jurisdiction-specific. In the United States, the injectable product is authorised for premenopausal women with acquired, generalised hypoactive sexual desire disorder, a diagnosis that requires documented distress. It is not approved for men, for postmenopausal women, or for use alongside hormonal contraceptives under the approved labelling. Outside regulated markets, the same peptide is frequently sold as a research chemical, where identity, purity, and sterility are not independently verified.
Bremelanotide is a synthetic cyclic heptapeptide developed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and appetite signalling. Its structure contains seven amino acid residues joined by a lactam bridge that closes the ring between two side chains. The molecular formula is C50H68N14O10 and the nominal molecular mass is near 1025 daltons. Much of the early laboratory literature refers to the same molecule by the development code PT-141.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H68N14O10 | Cyclic heptapeptide backbone |
| Molecular mass | Approximately 1025 Da | Nominal mass of the free peptide |
| Appearance | White to off-white lyophilised powder | Typical for purified synthetic peptides |
| Solubility class | Freely soluble in water | Organic solubility is limited |
| Typical storage temperature | −20 °C or below | Protect from moisture and light |
PT-141 is the research code for bremelanotide, a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone. The molecule belongs to the melanocortin receptor agonist family and shows highest affinity for the MC4 receptor subtype, with weaker activity at MC1, MC3 and MC5. Its structure retains the core His-Phe-Arg-Trp sequence that defines melanocortin recognition, while cyclization and terminal modifications improve metabolic stability relative to the parent hormone. Early work classified the compound as a centrally acting agent rather than a peripherally acting vasodilator, which shaped subsequent development priorities.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.
Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.
The compound binds several melanocortin receptor subtypes rather than a single target, with the strongest functional activity reported at MC4R and measurable activity at MC1R, MC3R and MC5R. MC4R populations are dense in hypothalamic nuclei that integrate energy balance, autonomic tone and reproductive behaviour, which is the anatomical basis for the proposed pro-desire effect. Because binding is not subtype-selective, pigmentary and vascular effects accompany central activity. Improving subtype selectivity is an active area of analogue design. Direct causal mapping from receptor occupancy to reported desire change in humans is not fully established.
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Published discussion sits at the intersection of peptide chemistry, neuroendocrinology and sexual medicine. Trial reports emphasise change scores on validated instruments, while mechanistic papers focus on hypothalamic circuits and receptor selectivity. Because placebo response in this field is large, effect sizes are usually reported with confidence intervals rather than as isolated averages. Reviews note that female and male data sets are not interchangeable and should be read separately. Diagnostic terminology has been revised over time, which complicates comparison between older and newer studies.
=== Itching === Itching tends not to be a severe problem when opioids are used for pain relief, but antihistamines are useful for counteracting itching when it occurs. Non-sedating antihistamines such as fexofenadine are often preferred as they avoid increasing opioid induced drowsiness. However, some sedating antihistamines such as orphenadrine can produce a synergistic pain relieving effect permitting smaller doses of opioids be used. Consequently, several opioid/antihistamine combination products have been marketed, such as Meprozine (meperidine/promethazine) and Diconal (dipipanone/cyclizine), and these may also reduce opioid induced nausea.
=== Legal status === Cipaglucosidase alfa is available in the UK, since June 2021, under the Early Access to Medicines Scheme. In December 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Pombiliti, intended for the treatment of glycogen storage disease type II (Pompe disease). The applicant for this medicinal product is Amicus Therapeutics Europe Limited. Cipaglucosidase alfa was approved for medical use in the European Union in March 2023.
== Public consumption == The center at the Ames Research Center in California began researching how to allow visitors to taste astronaut food in 1973. They contacted American Outdoor Products and Backpacker's Pantry, the latter becoming a known source for freeze-dried meals like stews and even pasta dishes for serious campers and backpackers. NASA/AMES worked with American Outdoor Products to produce the world first freeze-dried ice cream and Astronaut Foods with the goal to allow people to see what space food tastes like.
Primary algae are those with "primary chloroplasts", i.e. chloroplasts with two membranes, evolved through a single symbiogenetic event with an endosymbiont β-cyanobacterium as early as 1.6 Gya during the Mesoproterozoic. These algae are mainly grouped in the clade Archaeplastida (meaning "ancient plastid"), which includes the major groups Viridiplantae (green algae sensu lato and all land plants) and Rhodophyta (red algae) as well as the minor group Glaucophyta (grey algae). The chloroplasts of red algae have chlorophyll a and c (often) and phycobilins, with extra-plastid starch storage; green algae chloroplasts have chlorophyll a and b without phycobilins, with intra-plastid starch storage; while grey algae chloroplasts have chlorophylls similar to red algae, but with a peptidoglycan outer layer. Land plants (embryophytes) are pigmented similarly to green algae and likely evolved from the freshwater green algae clade Streptophyta, which is sister taxon to Chlorophyta (green algae sensu stricto) and the basal clade Prasinodermophyta. There is also a minor group of amoeboid protists with primary plastids evolved via different origin and at a much later date than archaeplastid chloroplasts. The four species of the euglyphid amoebae genus Paulinella, have cyanobionts (known as cyanelles) that perform photosynthesis, likely originated from the endosymbiosis of a α-cyanobacterium (probably an ancestral member of Chroococcales), about 90–140 Mya during the Cretaceous.
Sources: en.wikipedia.org
== Regulation == The cellular protein levels of IRS-1 are regulated by the Cullin-7 E3 ubiquitin ligase, which targets IRS-1 for ubiquitin mediated degradation by the proteasome. Different Serine phosphorylation of IRS-1, caused by various molecules, such as fatty acids, TNFα and AMPK, has different effects on the protein, but most of these effects include cellular re-localization, conformational and steric changes. These processes lead to decrease in Tyrosine phosphorylation by insulin receptors and diminished PI3K recruitment. Altogether, these mechanisms stimulate IRS-1 degradation and insulin resistance. Other inhibitory pathways include SOCS proteins and O-GlcNAcylation of IRS-1. SOCS proteins act by binding to IR and by interfering with IR phosphorylation of IRS-1, therefore attenuating insulin signaling. They can also bind to JAK, causing a subsequent decrease in IRS-1 tyrosine phosphorylation. During insulin resistance induced by hyperglycemia, glucose accumulates in tissues as its hexosamine metabolite UDP-GlcNAc. This metabolite if present in high amounts leads to O-GlcNAc protein modifications. IRS-1 can undergo this modification, which results in its phosphorylation and functional suppression.
Regardless of the IUD type, some potential side effects are similar for all IUDs. Some of these side effects include bleeding pattern changes, expulsion, and pelvic inflammatory disease (especially in the first 21 days after insertion). The occurrence of IUD migration to another location outside of the uterus is rare, with reported rates in medical literature varying between 0.1% and 0.9%. However, when migration occurs, it can lead to serious complications such as uterine perforation and, in rare cases, bladder perforation. Bladder perforation, while uncommon (affecting only 2% of migrated IUDs), can result in symptoms like urinary frequency, hematuria, and stone formation, often necessitating surgical intervention for removal. Regular monitoring and imaging, such as ultrasound or CT scans, are recommended to detect such complications early and ensure timely treatment. A small probability of pregnancy remains after IUD insertion, and when it occurs, there is a greater risk of ectopic pregnancy. Hormonal IUDs confer an increased risk of ovarian cysts. Mirena lists common (less than 1 in 10 women) side effects as including ovarian cysts, painful periods, increased vaginal discharge, headaches and depression. Hormonal IUDs have been associated with psychiatric symptoms, including depression, anxiety, and suicidal ideation, particularly in adolescents and young women, though evidence remains mixed.
Although scientifically obsolete because it does not meet the definition of a complementary color in which a neutral or black color must be mixed, it is still a model used in artistic environments, causing confusion about primary and complementary colors. It can be considered an approximation of the CMY color model. The RYB color model relates specifically to color in the form of paint and pigment application in art and design. Other common color models include the light model (RGB) and the paint, pigment and ink CMY color model, which is much more accurate in terms of color gamut and intensity compared to the traditional RYB color model, the latter emerging in conjunction with the CMYK color model in the printing industry.
Sources: en.wikipedia.org
The olive trade in southern Lebanon, which is the main source of income for many, was halted as farmers stopped their harvests in fear of the active shelling. According to Agriculture Minister Abbas Hajj Hassan, 40,000 olive trees have been burned down by fires caused by IDF shelling. The ministry has also said that 790 hectares of agricultural land have been damaged and 340 thousand farm animals have been lost. In total, the IDF has caused US$3 billion of agriculture losses. The Institute of International Finance predicted that Lebanon's GDP could decline by one percent by the end of 2023 and by 30 percent in 2024 in the event of further spillover of the war. According to the Council for the South, Israeli strikes have destroyed 1,700 buildings and damaged 14,000 others and caused US$500 million worth of damage on water, electricity, telecoms and other infrastructure.
Cardona completed his PhD at the University of Barcelona (2000–2005), where he studied developmental biology. He then undertook postdoctoral research on Drosophila neuroanatomy at UCLA (2005–2008). Between 2008 and 2011, Cardona was a Group Leader at the Institute of Neuroinformatics, jointly run by the University of Zurich and ETH Zurich. During this period, he developed computational and image-processing methods for neural circuit reconstruction and co-founded two influential open-source platforms that have become widely adopted in the neuroscience community. Cardona joined the Howard Hughes Medical Institute (HHMI) Janelia Research Campus in 2012, serving as Group Leader until 2019. In 2019, he was appointed Programme Leader at the MRC Laboratory of Molecular Biology and Professor at the University of Cambridge, where he leads research on whole-brain connectomics, circuit development, and structure–function relationships in neural systems.
Any protein that can be split into two parts and reconstituted non-covalently to form a functional protein may be used in a PCA. The two fragments however have low affinity for each other and must be brought together by other interacting proteins fused to them (often called "bait" and "prey" since the bait protein can be used to identify a prey protein, see figure). The protein that produces a detectable readout is called "reporter". Usually enzymes which confer resistance to nutrient deprivation or antibiotics, such as dihydrofolate reductase or beta-lactamase respectively, or proteins that give colorimetric or fluorescent signals are used as reporters. When fluorescent proteins are reconstituted the PCA is called Bimolecular fluorescence complementation assay. The following proteins have been used in split protein PCAs:
Supergrade 2–3% Weapons grade 3–7% Fuel grade 7–18% Reactor grade 18% or more A nuclear reactor that is used to produce plutonium for weapons therefore generally has a means for exposing 238U to neutron radiation and for frequently replacing the irradiated 238U with new 238U. A reactor running on unenriched or moderately enriched uranium contains a great deal of 238U. However, most commercial nuclear power reactor designs require the entire reactor to shut down, often for weeks, in order to change the fuel elements. They therefore produce plutonium in a mix of isotopes that is not well-suited to weapon construction. Such a reactor could have machinery added that would permit 238U slugs to be placed near the core and changed frequently, or it could be shut down frequently, so proliferation is a concern; for this reason, the International Atomic Energy Agency inspects licensed reactors often. A few commercial power reactor designs, such as the reaktor bolshoy moshchnosti kanalniy (RBMK) and pressurized heavy water reactor (PHWR), do permit refueling without shutdowns, and they may pose a proliferation risk. By contrast, the Canadian CANDU heavy-water moderated, natural-uranium fueled reactor can also be refueled while operating, but it normally consumes most of the 239Pu it produces in situ; thus, it is not only inherently less proliferative than most reactors, but can even be operated as an "actinide incinerator".
Sources: en.wikipedia.org
It is a synthetic cyclic peptide that acts as an agonist at melanocortin receptors. It is not a hormone replacement therapy and not a vasodilator in the usual clinical sense, although it does affect vascular tone. Chemically it belongs to the melanocortin analogue family.
PT-141 was the internal development code used during early research and it persists in older publications, conference abstracts, and informal listings. The code and the approved name refer to the same molecule. Its continued use reflects habit in the literature rather than any difference in substance.
No. The intranasal form was studied in trials but was never approved, and absorption through the nasal route varies considerably between individuals. Approved labelling covers a subcutaneous injection only. Any nasal product sold outside regulated channels falls outside verified manufacturing.
Purity is normally expressed as a percentage of total peak area from a chromatographic run. The value depends on the column, gradient and detection wavelength chosen. Results generated under different conditions are therefore not always interchangeable.